Fallon Michael J, Heck Jessica N
Department of Pharmacy, University of Wisconsin Hospital and Clinics F6/133, Madison, WI, USA
Department of Pharmacy, University of Wisconsin School of Pharmacy, Madison, WI, USA.
J Oncol Pharm Pract. 2015 Oct;21(5):388-92. doi: 10.1177/1078155214533368. Epub 2014 Jul 7.
Stevens-Johnson syndrome/toxic epidermal necrolysis overlap is an acute hypersensitivity reaction that compromises the integrity of mucous membranes and cutaneous tissue. While the pathophysiology of this syndrome has not been fully elucidated, it is commonly associated with the medication use and carries a significant mortality risk of approximately 30%. No commonalities among causative medications have been identified, and determining the offending agent can be challenging. This case report describes fatal Stevens-Johnson syndrome/toxic epidermal necrolysis overlap in a patient after receiving his first cycle of allopurinol, rituximab, and bendamustine treatment for non-Hodgkin's B-cell lymphoma. An analysis of FDA Medwatch adverse reaction case reports involving allopurinol, rituximab, and bendamustine is also presented.
史蒂文斯-约翰逊综合征/中毒性表皮坏死松解症重叠综合征是一种急性超敏反应,会损害黏膜和皮肤组织的完整性。虽然该综合征的病理生理学尚未完全阐明,但它通常与药物使用有关,且具有约30%的显著死亡风险。尚未确定致病药物之间的共性,确定致病药物可能具有挑战性。本病例报告描述了一名非霍奇金B细胞淋巴瘤患者在接受第一个周期的别嘌醇、利妥昔单抗和苯达莫司汀治疗后发生致命的史蒂文斯-约翰逊综合征/中毒性表皮坏死松解症重叠综合征。本文还对美国食品药品监督管理局(FDA)Medwatch中涉及别嘌醇、利妥昔单抗和苯达莫司汀的不良反应病例报告进行了分析。